Abstract

Anti-prion protein (PrP) monoclonal antibody 132, which recognizes mouse PrP amino acids 119–127, enables us to reliably detect abnormal isoform prion protein (PrPSc) in cells or frozen tissue sections by immunofluorescence assay, although treatment with guanidinium salts is a prerequisite. Despite the benefit of this mAb, the mechanism of PrPSc-specific detection remains unclear. Therefore, to address this mechanism, we analyzed the reactivities of mono- and bivalent mAb 132 to recombinant mouse PrP (rMoPrP) by enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). In ELISA, binding of the monovalent form was significantly weaker than that of the bivalent form, indicating that bivalent binding confers a higher binding stability to mAb 132. Compared with other anti-PrP mAbs tested, the reactivity of bivalent mAb 132 was easily affected by a decrease in antigen concentration. The binding kinetics of mAb 132 assessed by SPR were consistent with the results of ELISA. The dissociation constant of the monovalent form was approximately 260 times higher than that of the bivalent form, suggesting that monovalent binding is less stable than bivalent binding. Furthermore, the amount of mAb 132 that bound to rMoPrP decreased if the antigen density was too low to allow bivalent binding. If two cellular PrP (PrPC) are close enough to allow bivalent binding, mAb 132 binds to PrPC. These results indicate that weak monovalent binding to monomeric PrPC diminishes PrPC signals to background level, whereas after exposure of the epitope, mAb 132 binds stably to oligomeric PrPSc in a bivalent manner.

Highlights

  • Prion diseases are fatal neurodegenerative diseases in animals and humans, including bovine spongiform encephalopathy, scrapie in sheep and goats, and Creutzfeldt-Jakob disease in humans [1]

  • MAb 132 hardly reacts with native PrPC on the cell surface [28] but reacts with denatured PrPSc and PrPC in immunoblot analysis and with recombinant prion protein (PrP) in enzyme-linked immunosorbent assay (ELISA) [23], suggesting that this mAb is classified as a pan-PrP mAb

  • We used two expression systems such that two peptide chains could be co-expressed from a single plasmid (Fig 1B); one system was bicistronic expression using an internal ribosomal entry site (IRES) [24] and the other was C-terminal cleavage by ribosomal skipping using a self-cleavage 2A peptide from foot-and-mouth disease virus (F2A) peptide [25]

Read more

Summary

Introduction

Prion diseases are fatal neurodegenerative diseases in animals and humans, including bovine spongiform encephalopathy, scrapie in sheep and goats, and Creutzfeldt-Jakob disease in humans [1]. The causative agents of prion diseases, prions, are mainly composed of an abnormal isoform of prion protein (PrPSc), which is generated from a host-encoded cellular isoform. Mechanism of the PrPSc-specific detection by mAb132.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call